Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
Type 2 diabetes is the leading cause of end-stage renal disease (ESRD) in most industrialized countries in Europe. The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) Study evaluated the renal protective effects of losartan versus placebo on a background of non-ACE-I/non-AIIA conventional antihypertensive therapy in 1513 patients with type 2 diabetes and nephropathy. Losartan reduced the incidence of doubling of serum creatinine, end-stage renal disease (ESRD), or death by 16% (P=0.022) and reduced the risk of progression to ESRD, defined as the initiation of dialysis or transplantation, by 29% (P=0.002). We set out to estimate the potential effect of losartan on the burden and costs associated with ESRD over 3.5 years in the European Union (EU). The risk reduction in new cases of ESRD was calculated by combining type 2 diabetes population estimates for the EU with the percent absolute risk reduction of ESRD in patients treated with losartan as observed in RENAAL. The number of days each patient experienced ESRD was defined as the length of time from onset of ESRD until the minimum of death or 3.5 years. ESRD-free person-years avoided with losartan treatment were calculated by combining the population estimate with the ESRD days avoided divided by number of days in a year. ESRD costs from Germany were used to approximate the potential cost savings from reduced time with ESRD and fewer ESRD cases on a EU wide basis. There are approximately 700,000 diagnosed type 2 diabetes patients with proteinuria (urine albumin/creatinine >or=300 mg/g) in the EU. The addition of losartan to the treatment regimen of these patients is expected to lead to a reduction of 44,100 cases of ESRD, 64,400 fewer person-years with ESRD, and reduce ESRD-related costs by euro 2.6 billion over 3.5 years based on RENAAL data. Treatment with losartan not only reduced the incidence of ESRD, but also can result in substantial cost savings in the European Union.
Gerth
William C
WC
Worldwide Outcomes Research, Merck & Co., Inc., Whitehouse Station, New Jersey 08889, USA. william_gerth@merck.com
Remuzzi
Giuseppi
G
Viberti
GianCarlo
G
Hannedouche
Thierry
T
Martinez-Castelao
Alberto
A
Shahinfar
Shahnaz
S
Carides
George W
GW
Brenner
Barry
B
D047228:Angiotensin II Type 1 Receptor Blockers / Q000191:economics / Q000627:therapeutic use*; D017046:Cost Savings; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000191:economics / Q000401:mortality; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000191:economics / Q000209:etiology / Q000401:mortality; D018450:Disease Progression; D005060:Europe / Q000453:epidemiology; D005062:European Union; D017048:Health Care Costs; D006801:Humans; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000191:economics / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D019808:Losartan / Q000191:economics / Q000627:therapeutic use*; D018803:Models, Economic; D011507:Proteinuria / Q000188:drug therapy* / Q000191:economics / Q000209:etiology / Q000401:mortality; D011634:Public Health / Q000191:economics*; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D019808:Losartan